Lunit
Korean AI for cancer screening and digital pathology
Overview
Lunit is a Korean medical-AI company building FDA-cleared software for cancer detection and biomarker analysis. Its INSIGHT suite supports radiology cancer screening (including mammography and chest imaging) while the SCOPE platform applies AI to digital pathology and immunotherapy-response biomarkers. Its products are deployed across thousands of medical institutions in dozens of countries.
ASEAN Perspective
Lunit in Southeast Asia
ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).
Lunit is among the most clinically validated medical-AI companies in Asia, with FDA-cleared cancer-screening products and a pathology platform used in research partnerships with major pharma. Its evidence base and global institutional deployment lend real credibility.
It is a regulated clinical product sold to hospitals and pharma rather than a general-purpose tool, with no public API and procurement-led pricing. For oncology imaging and pathology it is a leading specialist; everyday relevance for general users is naturally limited.
About this listing
This entry was compiled from publicly available data including Lunit's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Lunit unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Lunit directly →
Spotted something out of date? Suggest an update →
More in Other
